Financial Comparison: Thermo Fisher Scientific (NYSE:TMO) versus iSpecimen (NASDAQ:ISPC)

iSpecimen (NASDAQ:ISPC) and Thermo Fisher Scientific (NYSE:TMO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings & Valuation

This table compares iSpecimen and Thermo Fisher Scientific”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93 million	2.01	-$10.49 million	($56.44)	-0.03
Thermo Fisher Scientific	$44.56 billion	5.16	$6.70 billion	$18.59	33.45

Thermo Fisher Scientific has higher revenue and earnings than iSpecimen. iSpecimen is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

13.6% of iSpecimen shares are held by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are held by institutional investors. 12.2% of iSpecimen shares are held by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares iSpecimen and Thermo Fisher Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
Thermo Fisher Scientific	15.04%	17.09%	8.12%

Analyst Ratings

This is a summary of current ratings and target prices for iSpecimen and Thermo Fisher Scientific, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1	0	0	0	1.00
Thermo Fisher Scientific	0	6	16	1	2.78

Thermo Fisher Scientific has a consensus target price of $619.41, suggesting a potential downside of 0.40%. Given Thermo Fisher Scientific’s stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than iSpecimen.

Volatility and Risk

iSpecimen has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

Summary

Thermo Fisher Scientific beats iSpecimen on 13 of the 15 factors compared between the two stocks.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.